Resalis Therapeutics

Resalis Therapeutics' transformative approach to metabolic diseases targets key regulators of multiple pathways in obesity and fatty liver disease. The company is leveraging its deep understanding of non-coding RNA drug modalities and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment option that delivers disease-modifying effects, including sustained weight loss and reduction in hepatic steatosis. Based on strong preclinical evidence, Resalis will rapidly advance RES-010 into clinical trials for a range of metabolic disorders.